Analysis of drug consumption among ambulatory patients in a drug agency of Northern France (Lens);Analyse de la consommation de drogues au sein de la population consultant le centre de soins spécialisés pour personnes toxicomanes de Lens

Annales de Medecine Interne

Volumn 154, Issue SPEC. ISS. 1, 2003, Pages

  Brunelle, Emmanuel ^a  

^a Ctr Traitement Dependances Le Sq ^*  (France)

Author keywords

Buprenorphine; Drug agency; Drugs; Lens (France); Opiate dependent patients

Indexed keywords

BUPRENORPHINE; ILLICIT DRUG; PSYCHOTROPIC AGENT; NARCOTIC AGENT; NARCOTIC ANTAGONIST;

ADOLESCENT; ADULT; AGE; AMBULATORY CARE; ARTICLE; DRUG ABUSE; DRUG MISUSE; DRUG USE; DRUG UTILIZATION; FEMALE; FRANCE; GENDER; HUMAN; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MOTIVATION; OPIATE ADDICTION; PRESCRIPTION; ANALYSIS OF VARIANCE; DRUG DEPENDENCE TREATMENT; MIDDLE AGED; NONPARAMETRIC TEST; QUESTIONNAIRE; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; BUPRENORPHINE; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; NARCOTIC ANTAGONISTS; NARCOTICS; OPIOID-RELATED DISORDERS; QUESTIONNAIRES; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; SUBSTANCE ABUSE TREATMENT CENTERS;

EID: 18544408885     PISSN: 0003410X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Observatoire Français des Drogues et des Toxicomanies. Usagers de drogues injectables et buprénorphine haut dosage. Analyse des déviations de son utilisation. Paris: OFDT, 2001.
2. THIRION X, MICALLEF J, BARRAU K, et al.: Recent evolution in opiate dependence in France during generalisation of maintenance treatment. Drug Alcohol Depend, 2001; 61: 281-5.
3. DUBURCQ A, CHARPAK Y, BLIN P, MADEC L: Two years follow-up of a heroin users cohort treated with high dosage buprenorphine. Results of the SPESUB study (pharmacoepidemiologic follow-up of general practice Subutex®). Rev Epidemiol Sante Publique, 2000; 48: 363-73.
4. DE DUCLA M, GAGNON A, MUCCHIELLI A, ROBINET S, VELLAY A: Suivi de patients pharmaco-dépendants aux opiacés traités par buprénorphine haut dosage à partir de réseaux de soins. Étude rétrospective nationale. Expérience de médecins généralistes françals. Ann Med Interne, 2000; 151 (suppl A): A27-32.
5. BRUNELLE E, ROTILY M: A cluster of nine overdoses (one fatal) related to methadone in the north of France: a lesson for drug policy in frontier regions. Addiction, 2002; 97: 1221-3.
6. BRUNELLE E: Analyse de la file active des consultants d'un centre spécialisé en toxicomanie dans le nord de la France. Ann Med Interne, 2002; 153 (Suppl): 2S47-9.
7. CHEVALLIER E: Estimations locales de la prévalence de l'usage d'opiacés et de cocaïne en France: une étude multicentrique à Lens, Lille, Marseille, Nice et Toulouse. Paris: OFDT, 2001: 55-67.
8. KOKKEVI A, RICHARDSON C, PALERMOU B, LEVENTAKOU V: Reliability of drug dependents' self-reports. Drug Alcohol Depend, 1997; 14: 55-61.
9. MENOYO C, LAMIKIZ E, ZULAIKA D, URCELAI A, ZUBIA I, MARTINEZ DE PANCORBO M: The validation of statements by IDUs based on the analysis of blood traces on their used syringes. AIDS Care, 1998; 10: 409-14.
10. OBADIA Y, PERRIN V, FERONI I, VLAHOV D, MOATTI JP: Injecting misuse of buprenorphine among French drug users. Addiction, 2001; 96: 267-72.
11. THIRION X, BARRAU K, MICALLEF J, HARAMBURU F, LOWENSTEIN W, SANMARCO JL: Traitements de substitution de la dépendance aux opiacés dans les centres de soins: le programme OPPIDUM des Centres d'Évaluation et d'Information sur la Pharmacodépendance. Ann Med Interne, 2000; 151 (suppl A): A10-7.
12. BARRAU K, THIRION X, MICALLEF J, CHUNIAUD-LOUCHE C, BELLEMIN B, SANMARCO JL: Comparison of methadone and high dosage buprenorphine users in French care centres. Addiction, 2001; 96: 1433-41.
13. AUGE-CAUMON Mj, BLOCH-LAINÉ JF, LOWENSTEIN W, MOREL À: L'accès à la méthadone en France. Bilans et recommandations. Rapport réalisé à la demande de Bernard Kouchner, ministre délégué à la santé, 2001.
14. COMER SD, COLLINS ED, FISCHMAN MW: Intravenous buprenorphine self-administration by detoxified heroin abusers. J Phannacol Exp Ther, 2002; 301: 266-76.
15. MOREL A: Traitements de substitution à la buprénorphine: l'expérience française. Toxibase, 2000; 3: 1-37.
16. SEYER D, DIF C, BALTHAZARD G, SCIORTINO V: Traitement de substitution par buprénorphine-haut-dosage: les recommandations sont-elles toujours suivies? Therapie, 1998; 53: 349-54.
17. FONTAA V, BRONNER C: Persistance de la pratique d'injection chez des patients substitués par méthadone ou buprénorphine haut dosage. Ann Med Interne, 2001; 152 (Suppl): 2S59-69.
18. GASQUET I, LANCON C, PARQUET P: Facteurs prédictifs de la réponse au traitement par substitutif par buprénorphine haut dosage: étude naturaliste en Médecine Générale. Encéphale, 1999; 25: 645-51.
19. VIGNAU J: Un modèle de compréhension de l'addiction. Encéphale, 2002; Hors série 8: 91-101.
20. KINTZ P: Deaths involving buprenorphine: a compendium of French cases. Forensic Sci Int, 2001; 121: 65-9.
21. AVANTS SK, MARGOLIN A, KOSTEN TR: Cocaine abuse in methadone maintenance programs: integrating pharmacotherapy with psychosocial interventions. J Psychoactive Drugs, 1994; 26: 137-46.
22. CONDELLI WS, FAIRBANK JA, DENNIS ML, RACHAL JV: Cocaine use by clients in methadone programs: significance, scope, and behavioral interventions. J Subst Abuse Treat, 1991; 8: 203-12.
23. MELLO NK, MENDELSON JH, BREE MP, LUKAS SE: Buprenorphine suppresses cocaine self-administration by rhesus monkeys. Science, 1989; 245: 859-62.
24. MELLO NK, MENDELSON JH, LUKAS SE, GASTFRIEND DR, TEOH SK, HOLMAN BL: Buprenorphine treatment of opiate and cocaine abuse: clinical and preclinical studies. Harv Rev Psychiatry, 1993; 1: 168-83.
25. SCHOTTENFELD RS, PAKES JR, OLIVETO A, ZIEDONIS D, KOSTEN TR: Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry, 1997; 54: 713-20.
26. LUCIDARME D, FOUTREIN P, CREUSY C, et al.: Prevalence of hepatitis C, B and D markers and histopathological aspects in a group of intravenous drug addicts. Gastroenterol Clin Biol, 1994; 18: 964-8.
27. CLAUDON-CHARPENTIER A, HOIBIAN M, GLASSER P, LALANNE H, PASQUALI JL: Drug-addicted prisoners: seroprevalence of human immunodeficiency virus and hepatitis B and C virus soon after the marketing of buprenorphine. Rev Med Interne, 2000; 21: 505-9.
28. BOURLIERE M, BARBEIN JM, ROTILY M, et al.: Epidemiological changes in hepatitis C virus genotypes in France: evidence in intravenous drug users. J Viral Hepat, 2002; 9: 62-70.
29. THOMAS DL, RICH JD, SCHUMAN P, SMITH DK, ASTEMBORSKI JA, NOLT KR, KLEIN RS: Multicenter evaluation of hepatitis C RNA levels among female injection drug users. J Infect Dis, 2001; 183: 973-6.
30. MATHEI C, BUNTINX F, VAN DAMME P: Is the prevalence of hepatitis C virus (HCV) RNA in anti-HCV-positive injection drug users positively correlated with age? J Infect Dis, 2001; 184: 659-60.
31. FORNS X, PAYETTE PJ, MA X, et al.: Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV. Hepatology, 2001; 32: 618-25.
32. BASSETT SE, GUERRA B, BRASKY K, MISKOSKY E, HOUGHTON M, KLIMPEL GR, et al.: Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. Hepatology, 2001; 33: 1479-87.
33. MEHTA SH, COX A, HOOVER DR: Protection against persistence of hepatitis C. Lancet, 2002; 359: 1478-83.
34. DUESBERG U, GEULEN O, SCHNEIDERS AM: Transient loss of t-cell reactivity in a patient with hepatitis c virus reinfection. Digestion, 2001; 64: 66-70.
35. GOMEZ-FLORES R, WEBER RJ: Differential effects of buprenorphine and morphine on immune and neuroendocrine functions following acute administration in the rat mesencephalon periaqueductal gray. Immunopharmacology, 2000; 48: 145-56.